Ziyu II inhibits CRC cells growth both in vitro andin vivo
To examine whether Ziyu II exhibits an antitumor effect against CRC, CRC
cell lines (HCT116, DLD-1, HT29, SW48, SW620, RKO) and noncancerous
colorectal cell line (NCM460) were treated with different dose of Ziyu
II. MTT assay showed that Ziyu II markedly inhibited the growth of CRC
cells in a dose-dependent manner, whereas the IC50 value in NCM460 cells
were much higher than those in CRC cells (Fig.1B). Consistently, the
proliferation of CRC cells was significantly decreased upon Ziyu II
treatment, as evidenced by reduced colony formation and EdU
incorporation (Fig.1C-E). Then we performed LDH release assay and found
that Ziyu II damaged the integrity of plasma membrane (Fig.1F). In
summary, these results demonstrated that Ziyu II inhibits the growth of
CRC cells in vitro .
To further ascertain the antitumor effect of Ziyu II on CRC growthin vivo , we generated a CRC xenograft model by
subcutaneously inoculating DLD-1 cells into nude mice. As shown in Fig.
1G and H, Ziyu II treatment markedly decreased the size and the weight
of xenografts when compared with the control group. In addition,
xenografts treated with Ziyu II grew at a slower rate than those treated
with placebo (Fig. 1I). Moreover, most of Ziyu II-treated tumors
displayed reduced Ki67 staining (Fig.1J and K). Moreover, we found that
Ziyu II treatment had no significant effect on the pathological features
of major organs, suggesting that Ziyu II has no obvious toxic or adverse
effect on mice (Fig. S1). Taken together, these data suggest that Ziyu
II inhibits the growth of CRC cells both in vitro andin vivo .